Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | GMPS | P49915 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 2/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | AHCY | P23526 | 8/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | NADK | O95544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160357 | 0.85 | ADORA3 (0.53) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL8949392 | 0.85 | ADORA2A (0.43) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL30216733 | 0.84 | EHMT1 (0.45) | ADORA3ADORA2AGMPSAHCYTAS1R3 | |
| SCHEMBL8677295 | 0.83 | ADORA2A (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL30139991 | 0.83 | ADORA2A (0.48) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL4751168 | 0.81 | ADORA2A (0.46) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL6650344 | 0.81 | ADORA2A (0.46) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL4830361 | 0.81 | ADORA2A (0.46) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL10604267 | 0.76 | PI4KA (0.47) | ADORA3ADORA2AGMPSPI4KAPI4K2B | |
| SCHEMBL5268052 | 0.76 | P2RX1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454263-B1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE MEDICINE INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9957272-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2018-05-01 | — | — | US | disclosed |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | VICTORIA LINK LIMITED (NZ) | 2017-06-15 | — | — | US | disclosed |
| US-9493465-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2016-11-15 | — | — | US | disclosed |
| EP-2049543-B1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | CALLAGHAN INNOVATION RES LTD (NZ) | 2014-11-05 | — | — | EP | disclosed |
| US-8383636-B2 | Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-02-26 | — | — | US | disclosed |
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-06-21 | — | — | US | disclosed |
| EP-2454263-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | The Albert Einstein College Of Medicine Of Yeshiva University (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2011-02-24 | — | — | US | disclosed |
| WO-2011008110-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
| EP-2049543-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008030118-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
| EP-1482977-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003074083-A1 | COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157479-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | ADORA3 750/4885ADORA2A 1340/4885GMPS 70/4885 |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | ADORA3 749/4885ADORA2A 1335/4885GMPS 71/4885 |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | MTAP, PNP, TYMP | ADORA3 160/4885ADORA2A 156/4885GMPS 59/4885 |
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | ADORA3 743/4885ADORA2A 509/4885GMPS 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.